GNPX

Genprex Inc. Common Stock (GNPX) | Rumor.io

Genprex

GNPX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,183

Bullish sentiment (50-day avg)79%

Price to earnings ratio0.08

Market capitalization2.3M

Earnings per share34.4

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-16.2M

Social

What share of all stock conversation is about GNPX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0.01% +0.01	0% 0	0% -0.01

Sep 28

$GNPX is trading at a huge discount to net cash per share, with cash/share still several times the price, even after a quarter of burn.
The stock has a strong potential for a bounce due to its low price and the possibility of a PR soon.
There are signs of potential volatility, with the 15-minute MACD crossing up, and some traders expecting a quick move in the stock.

Generated by AI

Sentiment

Of the messages about GNPX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +48.57	79.11% -20.89	79.75% -2.42	86.21% +0.44
Bearish	0% -48.57	20.89% +20.89	20.25% +2.42	13.79% -0.44

Bullish· Sep 23

The company has a very low float of 800k shares, making it susceptible to a potential squeeze, as seen in the $JAGX example.
Genprex Inc. has a significant cash position of $12.7M, which could support a substantial increase in stock price, potentially reaching a 500% rise to match the cash position.
The stock's current price is under $4, making it a relatively cheap buy, with a cash/sh ratio of $15, compared to its market cap, which could lead to a significant increase in value.

Bearish· Sep 23

The stock has been plagued by dilution, with the company having undergone multiple reverse splits, which has resulted in significant losses for shareholders.
The company's poor management has led to a pattern of premarket pump and dumps, followed by new lows, making it a high-risk investment opportunity.
The stock's technical analysis suggests a strong likelihood of hitting a new all-time low, with the current price being unsustainable in the long term.

Generated by AI

Topics

Of the messages about GNPX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	20%	42.86%	38.13%
Technical Analysis	—	80%	45.71%	18.73%
Analysts	—	0%	0%	39.27%
Controversies	—	0%	11.43%	0.24%
Macro	—	0%	0%	3.48%
Earnings	—	0%	0%	0.15%

Announcements· Aug 18

Genprex, Inc. (GNPX) has partnered with a leading U.S. Contract Development and Manufacturing Organization (CDMO) to scale up its diabetes gene therapy program for IND-enabling studies and future clinical trials.
The partnership enables Genprex to transition its gene therapy candidate to clinical-grade production, utilizing specialized CDMO expertise to scale complex biological processes.
Genprex has $27 in net cash per share and is trading at under $5 per share, with a reported float of approximately 400,000 shares, making it a highly liquid stock with significant market activity.

Technical Analysis· Oct 15

$GNPX is forming a cup and handle, a bullish chart pattern, and is showing signs of fresh momentum.
The stock's 200-day SMA is at $0.33.8, and the 9-period EMA is above the daily chart, indicating a potential bullish trend.
The stock is currently in an ascending channel, and a "descending wedge + demand zone" pattern is a potential development, but caution is advised below the VWAP ($0.32).

Generated by AI

Community

Of the messages about GNPX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	22.22%	53.37%	52.64%	50.69%
Newcomers	77.78%	46.63%	47.36%	49.31%

Regulars· Sep 28

The stock is trading at a significant discount to its net cash per share, with a cash value of ~$18 per share compared to its current price of ~$2.80.
The regulars are optimistic about the stock's potential to bounce back, with some expecting a big rebound despite the current downtrend.
The current market conditions, including the rate hike cycle and the decimation of nano cap stocks, are being cited as factors contributing to the stock's decline.

Newcomers· Sep 23

Many are focusing on the potential for $GNPX to break out, with some referencing its low float of around 800k shares and a current price of $15.
Several newcomers are excited about the catalyst news expected in H2 2026, with some speculating that it could lead to significant gains, similar to those seen with $JAGX.
A number of users are calling $GNPX a "sleeper" or "hidden gem" with a high potential for growth, and are recommending it as a cheap and undervalued investment opportunity.

Generated by AI

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), today announced that members of its executive leadership team will present at and participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16 in New York City. Genprex is a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes. The Company's lead oncology program is in clinical developmen

22d agoYahoo Finance

Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program

Andelyn Biosciences, a leading contract development and manufacturing organization, announced today that Genprex, Inc. has selected Andelyn to support scale-up manufacturing for its diabetes gene therapy program.

29d agoYahoo Finance

Genprex partners with CDMO for diabetes gene therapy manufacturing

1mo agoInvesting.com

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy program. This strategic selection allows for the transitio

1mo agoYahoo Finance

Genprex Regains Nasdaq Compliance, Listing Status Secured

Detailed price information for Genprex Inc (GNPX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Genprex partners with Roche Diagnostics on biomarker validation for NSCLC

Validation studies are expected to conclude by the end of 2026, with potential integration into the NSCLC clinical programme thereafter.

1mo agoYahoo Finance

Also Discussed

Investors talking about GNPX also mention

#	Name	Attention
1	Nanoviricides Inc.NNVC	0%0
2	Co-Diagnostics Inc.CODX	0%+0
3	Immix Biopharma, Inc.IMMX	0.03%+0.03
4	Scienture Holdings, Inc.SCNX	0%0
5	GRI Bio Inc.GRI	0%+0
6	Tevogen Bio Holdings Inc.TVGN	0%0
7	Neo-Concept International Group Holdings Limited Class A Ordinary SharesNCI	0.01%+0.01
8	VIVK - Vivakor, Inc.	——
9	MTEM - Molecular Templates, Inc.	——
10	Quoin Pharmaceuticals, Ltd. American Depositary SharesQNRX	0%0

Genprex Inc. Common Stock

Healthcare
Biotechnology

Genprex Inc. Common Stock is the equity security of Genprex Inc., a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The company’s current pipeline centers on gene-based technologies designed to deliver therapeutic genes using non-viral and nanoparticle delivery approaches. Its oncology work includes REQORSA immunogen therapy, which is being developed for lung cancer, while its diabetes program includes GPX-002, a gene therapy candidate aimed at addressing metabolic disease. Genprex Inc. operates in the healthcare and biotechnology sectors, where it contributes to the broader field of advanced genetic medicine and targeted treatment development. The common stock represents investor exposure to a company whose business is built around translational research, drug development, and clinical-stage innovation in diseases with significant unmet medical need.

Website

Location

3300 Bee Cave Road

Austin, TX, 78746

United States

Social

What share of all stock conversation is about GNPX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0.01% +0.01	0% 0	0% -0.01

Sep 28

$GNPX is trading at a huge discount to net cash per share, with cash/share still several times the price, even after a quarter of burn.
The stock has a strong potential for a bounce due to its low price and the possibility of a PR soon.
There are signs of potential volatility, with the 15-minute MACD crossing up, and some traders expecting a quick move in the stock.

Generated by AI

Sentiment

Of the messages about GNPX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +48.57	79.11% -20.89	79.75% -2.42	86.21% +0.44
Bearish	0% -48.57	20.89% +20.89	20.25% +2.42	13.79% -0.44

Bullish· Sep 23

The company has a very low float of 800k shares, making it susceptible to a potential squeeze, as seen in the $JAGX example.
Genprex Inc. has a significant cash position of $12.7M, which could support a substantial increase in stock price, potentially reaching a 500% rise to match the cash position.
The stock's current price is under $4, making it a relatively cheap buy, with a cash/sh ratio of $15, compared to its market cap, which could lead to a significant increase in value.

Bearish· Sep 23

The stock has been plagued by dilution, with the company having undergone multiple reverse splits, which has resulted in significant losses for shareholders.
The company's poor management has led to a pattern of premarket pump and dumps, followed by new lows, making it a high-risk investment opportunity.
The stock's technical analysis suggests a strong likelihood of hitting a new all-time low, with the current price being unsustainable in the long term.

Generated by AI

Topics

Of the messages about GNPX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	20%	42.86%	38.13%
Technical Analysis	—	80%	45.71%	18.73%
Analysts	—	0%	0%	39.27%
Controversies	—	0%	11.43%	0.24%
Macro	—	0%	0%	3.48%
Earnings	—	0%	0%	0.15%

Announcements· Aug 18

Genprex, Inc. (GNPX) has partnered with a leading U.S. Contract Development and Manufacturing Organization (CDMO) to scale up its diabetes gene therapy program for IND-enabling studies and future clinical trials.
The partnership enables Genprex to transition its gene therapy candidate to clinical-grade production, utilizing specialized CDMO expertise to scale complex biological processes.
Genprex has $27 in net cash per share and is trading at under $5 per share, with a reported float of approximately 400,000 shares, making it a highly liquid stock with significant market activity.

Technical Analysis· Oct 15

$GNPX is forming a cup and handle, a bullish chart pattern, and is showing signs of fresh momentum.
The stock's 200-day SMA is at $0.33.8, and the 9-period EMA is above the daily chart, indicating a potential bullish trend.
The stock is currently in an ascending channel, and a "descending wedge + demand zone" pattern is a potential development, but caution is advised below the VWAP ($0.32).

Generated by AI

Community

Of the messages about GNPX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	22.22%	53.37%	52.64%	50.69%
Newcomers	77.78%	46.63%	47.36%	49.31%

Regulars· Sep 28

The stock is trading at a significant discount to its net cash per share, with a cash value of ~$18 per share compared to its current price of ~$2.80.
The regulars are optimistic about the stock's potential to bounce back, with some expecting a big rebound despite the current downtrend.
The current market conditions, including the rate hike cycle and the decimation of nano cap stocks, are being cited as factors contributing to the stock's decline.

Newcomers· Sep 23

Many are focusing on the potential for $GNPX to break out, with some referencing its low float of around 800k shares and a current price of $15.
Several newcomers are excited about the catalyst news expected in H2 2026, with some speculating that it could lead to significant gains, similar to those seen with $JAGX.
A number of users are calling $GNPX a "sleeper" or "hidden gem" with a high potential for growth, and are recommending it as a cheap and undervalued investment opportunity.

Generated by AI

Genprex

Social

Sep 28

Bullish· Sep 23

Bearish· Sep 23

Announcements· Aug 18

Technical Analysis· Oct 15

Regulars· Sep 28

Newcomers· Sep 23

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program

Genprex partners with CDMO for diabetes gene therapy manufacturing

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Genprex Regains Nasdaq Compliance, Listing Status Secured

Genprex partners with Roche Diagnostics on biomarker validation for NSCLC

Also Discussed

Genprex Inc. Common Stock

Company Information

Location

Social

Sep 28

Bullish· Sep 23

Bearish· Sep 23

Announcements· Aug 18

Technical Analysis· Oct 15

Regulars· Sep 28

Newcomers· Sep 23

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program

Genprex partners with CDMO for diabetes gene therapy manufacturing

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Genprex Regains Nasdaq Compliance, Listing Status Secured

Genprex partners with Roche Diagnostics on biomarker validation for NSCLC

Also Discussed